BR112015026259A2 - combinações de ligantes de adrenoceptor alfa-2 e receptor sigma - Google Patents

combinações de ligantes de adrenoceptor alfa-2 e receptor sigma

Info

Publication number
BR112015026259A2
BR112015026259A2 BR112015026259A BR112015026259A BR112015026259A2 BR 112015026259 A2 BR112015026259 A2 BR 112015026259A2 BR 112015026259 A BR112015026259 A BR 112015026259A BR 112015026259 A BR112015026259 A BR 112015026259A BR 112015026259 A2 BR112015026259 A2 BR 112015026259A2
Authority
BR
Brazil
Prior art keywords
alpha
adrenoceptor
sigma receptor
receptor ligand
combination
Prior art date
Application number
BR112015026259A
Other languages
English (en)
Inventor
Zamanillo-Castanedo Daniel
Miguel Vela-Hernández José
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of BR112015026259A2 publication Critical patent/BR112015026259A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1/1 resumo combinações de ligantes de adrenoceptor alfa-2 e receptor sigma a invenção se refere a uma combinação que compreende um ligante sigma da fórmula geral (i) e composto agonista adrenérgico de alfa-2, um medicamento que compreende dita combinação de substância ativa, e o uso de dita combinação de substância ativa para a fabricação de um medicamento, particularmente para a profilaxia e/ou tratamento da dor.
BR112015026259A 2013-04-16 2014-04-15 combinações de ligantes de adrenoceptor alfa-2 e receptor sigma BR112015026259A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13382140.5A EP2792352A1 (en) 2013-04-16 2013-04-16 Alpha-2 adrenoreceptor and sigma receptor ligand combinations
PCT/EP2014/057608 WO2014170319A1 (en) 2013-04-16 2014-04-15 Alpha-2 adrenoceptor and sigma receptor ligand combinations

Publications (1)

Publication Number Publication Date
BR112015026259A2 true BR112015026259A2 (pt) 2017-07-25

Family

ID=48227118

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015026259A BR112015026259A2 (pt) 2013-04-16 2014-04-15 combinações de ligantes de adrenoceptor alfa-2 e receptor sigma

Country Status (16)

Country Link
US (1) US20160058771A1 (pt)
EP (2) EP2792352A1 (pt)
JP (1) JP2016516792A (pt)
KR (1) KR20150143754A (pt)
CN (1) CN105228606A (pt)
AR (1) AR095858A1 (pt)
AU (1) AU2014255837A1 (pt)
BR (1) BR112015026259A2 (pt)
CA (1) CA2908926A1 (pt)
HK (1) HK1219431A1 (pt)
MX (1) MX2015014441A (pt)
PH (1) PH12015502282A1 (pt)
RU (1) RU2015148766A (pt)
SG (1) SG11201508102XA (pt)
TN (1) TN2015000440A1 (pt)
WO (1) WO2014170319A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
KR20160097366A (ko) 2013-12-17 2016-08-17 라보라토리오스 델 드라. 에스테브.에스.에이. 세로토닌-노르에피네프린 재흡수 억제제들(SNRIs) 및 시그마 리셉터 리간드들 조합
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THERE

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7666882B2 (en) * 2002-11-15 2010-02-23 E.I. Du Pont De Nemours And Company Anthranilamide insecticides
BRPI0514692A (pt) 2004-08-27 2008-06-17 Esteve Labor Dr inibidores do receptor sigma
US8889173B2 (en) * 2008-04-18 2014-11-18 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
RU2572692C2 (ru) * 2009-05-15 2016-01-20 Рекро Фарма, Инк. Сублингвальные композиции дексмедетомидина и способы их применения
EP2292236A1 (en) 2009-08-14 2011-03-09 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention or treatment of pain induced by chemotherapy
ES2589045T3 (es) 2009-11-25 2016-11-08 Laboratorios Del Dr. Esteve, S.A. Sal de clorhidrato de 4-[2-[[5-metil-1-(2-naftalenil)-1H-pirazol-3-il]oxi]etil]morfolina
EP2335688A1 (en) 2009-11-25 2011-06-22 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical compositions comprising sigma receptor ligands
RS55046B1 (sr) 2010-02-04 2016-12-30 Esteve Labor Dr 4-[2-[[5-metil-1-(2-naftalenil)-1h-pirazol-3-il]oksi]etil]morfolin hidrohlorid i solvati
US20110269727A1 (en) * 2010-04-29 2011-11-03 Toledano Annette C Composition to reduce allodynic back pain and related method of use
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2426111A1 (en) 2010-08-09 2012-03-07 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms
EP2460519A1 (en) 2010-12-03 2012-06-06 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in bone cancer pain
EP2524694A1 (en) * 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain

Also Published As

Publication number Publication date
RU2015148766A3 (pt) 2018-03-29
KR20150143754A (ko) 2015-12-23
PH12015502282A1 (en) 2016-02-01
SG11201508102XA (en) 2015-11-27
EP2792352A1 (en) 2014-10-22
JP2016516792A (ja) 2016-06-09
EP2986284A1 (en) 2016-02-24
CA2908926A1 (en) 2014-10-23
TN2015000440A1 (en) 2017-01-03
WO2014170319A1 (en) 2014-10-23
MX2015014441A (es) 2016-06-21
HK1219431A1 (zh) 2017-04-07
CN105228606A (zh) 2016-01-06
RU2015148766A (ru) 2017-05-18
AR095858A1 (es) 2015-11-18
AU2014255837A1 (en) 2015-11-05
US20160058771A1 (en) 2016-03-03

Similar Documents

Publication Publication Date Title
BR112015026259A2 (pt) combinações de ligantes de adrenoceptor alfa-2 e receptor sigma
CY1120703T1 (el) Ετεροκυκλικες ενωσεις και χρησεις αυτων
PH12016500356A1 (en) Nsaid and sigma receptor ligand combinations
CR20150481A (es) Composición farmacéutica de clorhidrato de s-ketamina
CR20150480A (es) Composición farmacéutica de clorhidrato de s-cetamina
JO3452B1 (ar) بنزاميدات أمينو اريل مغاير كمثبطات كيناز
NI201600071A (es) Compuestos de inhibidor de autotaxina
BR112015027704A2 (pt) Composto, uso do mesmo e composição farmacêutica antibacteriana
DOP2016000253A (es) Nuevos compuestos
PH12016501095A1 (en) Gabapentinoids and sigma receptor ligands combinations
CL2016001587A1 (es) Derivado basado en 1,2-naftoquinona y método de preparación del mismo.
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
PH12016501096A1 (en) SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
BR112016007620A2 (pt) composto, medicamento, e, uso de um composto
CO7101239A2 (es) Composiciones derivadas de la quitosana
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
BR112016012552A8 (pt) derivado de cromona como um antagonista do receptor d3 de dopamina, seu uso e sua composição farmacêutica
UY35823A (es) Profármacos de antagonista de nmda
CR20150092A (es) Derivados de diazepinona útiles para el tratamiento del síndrome x frágil, enfermedad de parkinson o enfermedad del reflujo
BR112015024571A2 (pt) compostos de complexo de ferro(iii), medicamento, e, composição
PL401992A1 (pl) 2-benzoiloamino-5-(izochinolin-3-ylo)-1,3,4-tiadiazol, sposób jego wytwarzania oraz zastosowanie medyczne
PL400584A1 (pl) Zastosowanie medyczne 3-(tiofen-2-ylo)-1,2,4-triazolo-5-tionu

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]